From Ruhr University Eye Hospital, Bochum, Germany.
From Ruhr University Eye Hospital, Bochum, Germany.
J Cataract Refract Surg. 2017 Jun;43(6):789-795. doi: 10.1016/j.jcrs.2017.03.036.
To evaluate the safety and efficacy of photorefractive intrastromal corneal crosslinking (CXL) in low myopia.
Ruhr University Eye Hospital, Bochum, Germany.
Prospective case series.
Healthy eyes with myopia or myopic astigmatism had photorefractive intrastromal CXL using the Mosaic system to apply ultraviolet-A (UVA) 365 nm (30 mW/cm) irradiance (total calculated UVA dose of 10 J/cm or 15 J/cm) with riboflavin 0.1% solution. Efficacy was determined by the change in the manifest refraction spherical equivalent (MRSE), uncorrected distance visual acuity (UDVA), and corneal curvature. Safety was determined by the corrected distance visual acuity (CDVA), slitlamp biomicroscopy, endothelial cell count, and adverse events.
Twenty-six eyes of 14 patients with a mean age of 30.8 years ± 9.3 (SD) were included. There were statistically significant improvements in UDVA 1, 3, and 6 months postoperatively (all P < .001). A significant improvement in CDVA was observed (P = .02). Improvements in the mean manifest sphere and MRSE versus baseline were noted at all visits (P < .001), with a mean change of 0.99 ± 0.47 diopter (D) and 0.97 ± 0.48 D, respectively, by 6 months postoperatively. Significant reductions in corneal curvature versus baseline occurred at all follow-up visits (all P < .05). At 1 month, there were no significant changes in the endothelial cell density (P = .282) or number of cells (P = .069). No safety issues or complications were reported.
The findings show that patterned CXL using a custom CXL system is safe and effective for reducing myopic refractive error.
评估低近视患者光致折射性角膜间质交联（CXL）的安全性和有效性。
德国波鸿鲁尔大学眼科医院。
前瞻性病例系列。
使用 Mosaic 系统对近视或近视散光的健康眼进行光致折射性角膜间质 CXL，应用 365nm 紫外线-A（UVA）（30mW/cm）辐照度（总计算 UVA 剂量为 10J/cm 或 15J/cm），并用 0.1%核黄素溶液处理。通过测量等效球镜（MRSE）、未矫正远视力（UDVA）和角膜曲率的变化来评估疗效。通过矫正远视力（CDVA）、裂隙灯显微镜、内皮细胞计数和不良事件来评估安全性。
纳入 14 例患者的 26 只眼，平均年龄 30.8 岁±9.3（标准差）。术后 1、3 和 6 个月 UDVA 有统计学显著改善（均 P<0.001）。CDVA 显著提高（P=0.02）。所有随访中均观察到平均角膜曲率和 MRSE 与基线相比有显著改善（均 P<0.001），术后 6 个月平均变化分别为 0.99±0.47 屈光度（D）和 0.97±0.48 D。所有随访中角膜曲率与基线相比均显著降低（均 P<0.05）。术后 1 个月，内皮细胞密度（P=0.282）或细胞数量（P=0.069）无显著变化。未报告安全性问题或并发症。
研究结果表明，使用定制 CXL 系统进行图案化 CXL 对于减少近视屈光不正安全有效。
